Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naive Prostate Cancer
| Autor: | Michel Soulié, Gwenaelle Gravis, Laurien M. Buffart, Muriel Habibian, Florence Joly, Joost Dekker, Henk M.W. Verheul, Patricia Marino, A.M.J. Braamse, Karim Fizazi, Jean-Marie Boher, Inge R. H. M. Konings, Stéphane Oudard, Claudia S. E. W. Schuurhuizen |
|---|---|
| Přispěvatelé: | Bidaut, Ghislain, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Psychiatry, APH - Mental Health, Epidemiology and Data Science, APH - Health Behaviors & Chronic Diseases, CCA - Cancer Treatment and quality of life, Medical oncology, APH - Aging & Later Life, CCA - Cancer Treatment and Quality of Life, Medical Psychology |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Antineoplastic Agents Hormonal Drug-Related Side Effects and Adverse Reactions [SDV]Life Sciences [q-bio] 030232 urology & nephrology Docetaxel Severity of Illness Index law.invention 03 medical and health sciences 0302 clinical medicine Quality of life Randomized controlled trial law Surveys and Questionnaires Internal medicine Antineoplastic Combined Chemotherapy Protocols Severity of illness Humans Medicine Longitudinal Studies Patient Reported Outcome Measures Prospective Studies Progression-free survival Adverse effect Prospective cohort study Aged Aged 80 and over business.industry Prostatic Neoplasms Androgen Antagonists Middle Aged Progression-Free Survival 3. Good health Clinical trial [SDV] Life Sciences [q-bio] Oncology 030220 oncology & carcinogenesis Toxicity Goserelin Quality of Life business |
| Zdroj: | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (12), pp.1481-1488. ⟨10.6004/jnccn.2018.7069⟩ Schuurhuizen, C S E W, Marino, P, Braamse, A M J, Buffart, L M, Joly, F, Fizazi, K, Habibian, M, Boher, J-M, Soulie, M, Oudard, S, Konings, I R H M, Verheul, H M W, Dekker, J & Gravis, G 2018, ' Impact of patient-and clinician-reported cumulative toxicity on quality of life in patients with metastatic castration-naïve prostate cancer ', Journal of the national comprehensive cancer network, vol. 16, no. 12, pp. 1481-1488 . https://doi.org/10.6004/jnccn.2018.7069 Journal of the national comprehensive cancer network, 16(12), 1481-1488. Cold Spring Publishing LLC Journal of the National Comprehensive Cancer Network, 16(12), 1481-1488. Cold Spring Publishing LLC |
| ISSN: | 1540-1405 |
| DOI: | 10.6004/jnccn.2018.7069 |
| Popis: | International audience; Background: Current toxicity evaluation is primarily focused on high-grade adverse events (AEs) reported by clinicians. However, the cumulative effect of multiple lower-grade AEs may also impact patients' quality of life (QoL). Further, patient-reported toxicity may be more representative of patients' treatment experiences. This study aimed to determine whether cumulative toxicity comprising all-grade AEs is more associated with QoL than cumulative toxicity comprising high-grade AEs only, and whether patient-reported cumulative toxicity is more associated with QoL than clinician-reported cumulative toxicity. Methods: Patients with metastatic castration-naive prostate cancer participating in the phase III GETUG-AFU 15 trial completed questionnaires on AEs (at 3 and 6 months) and QoL (at baseline and 3 and 6 months). Clinicians reported AEs during clinical visits. Cumulative toxicity scores were calculated for clinicians and patients in 3 ways: total number of high-grade AEs, total number of all-grade AEs, and total number of all AEs multiplied by their grade (severity score). Relationships between cumulative toxicity scores and QoL were studied using longitudinal regression analyses; unstandardized (B) and standardized regression coefficients (beta) are reported. Results: Of 385 patients, 184 with complete QoL and toxicity data were included. Clinician-reported all-grade AEs (B, -2.2; 95% CI, -3.3 to -1.1; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|